Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
The last two decades have provided far more options f both patients and their physicians in the treatment of diabetes mellitus. While dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been approved for nearly two decades, sodium–glucose cotrans...
Saved in:
| Main Authors: | Basavana Goudra, Geno J. Merli, Michael Green |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/1/4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord
by: Sing-Ong Lee, et al.
Published: (2024-11-01) -
Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis
by: Yao Wang, et al.
Published: (2025-08-01) -
Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes
by: Shubham Agarwal, et al.
Published: (2025-05-01) -
The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required
by: Alan J. Sinclair, et al.
Published: (2025-01-01) -
Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand
by: Lynne Chepulis, et al.
Published: (2025-03-01)